Arcoma receives first order on the new product, OMNERA 500A
2021-06-10
PRESSRELEASE
Arcoma receives first order on the new product, OMNERA 500A
Arcoma AB has received the first order on the new product OMNERA 500A.
The OMNERA 500A is a new X-ray system developed with focus on efficient workflow, safety and ease of use. The ergonomic design simplifies and optimizes positioning and has been carefully designed to facilitate disinfection. OMNERA 500A is equipped with the latest touch screen technology and a new user interface which creates simplicity and efficiency for the user. A new wall stand with motorized tilt simplifies positioning and an updated X-ray table improves patient and user experience.
The order is placed by Canon Medical systems USA, Arcoma's partner in the US and will be delivered in June 2021.
"It feels great to start sales of our new product OMNERA 500A in the US market. The US is a large, important and central market in our continued growth. We are now looking forward to growing the business together with our partner Canon Medical Systems USA" , says Sanna Rydberg, CEO of Arcoma AB.
About Canon Medical Systems USA
Canon Medical Systems USA, Inc., headquartered in Tustin, Calif., markets, sells, distributes and services radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and interventional X-ray equipment. For more information, visit Canon Medical Systems’ website at https://us.medical.canon.
About Canon Medical Systems Corporation
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound, Vascular and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. For more information, visit the Canon Medical website: https://global.medical.canon.
OMNERA is a registered trademark of CANON MEDICAL SYSTEMS USA, INC. Made for Life is a trademark of Canon Medical Systems Corporation. CXDI is registered trademarks of Canon in the United States and may also be registered trademarks or trademarks in other countries.
About Arcoma
Arcoma, with long experience in the industry, is a leading provider of integrated digital X-ray systems with high quality and advanced technology. Arcoma’s products offer the latest digital imaging technology combined with technically advanced moving positioning systems and ergonomic Scandinavian design. Arcoma offers the customers complete, configurable and functional digital x-ray systems. The company's products are sold through retailers as well as OEM customers and today there are over 3,500 of Arcoma’s X-ray systems installed worldwide. Arcoma is listed on Nasdaq First North. For more information about Arcoma, please visit www.arcoma.se
For more information, please contact:
Sanna Rydberg, Telefon: +46 706 069548, E-mail: sanna.rydberg@arcoma.se. The information was submitted, through the CEO, for publication on June 10, 2021 at 10 AM.
For more IR-related information and the possibility of pressrelease prenumeration, please visit our IR page: www.arcoma.se/about-us/investors/
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Nokia Deepfield global analysis shows most DDoS attacks originate from fewer than 50 hosting companies14.6.2021 14:00:00 CEST | Press release
Press Release Nokia Deepfieldglobalanalysis shows most DDoS attacks originate from fewer than 50 hosting companies In-depth analysis across large sample of networks globally fingerprints and traces origins of most DDoS attacks (by frequency and traffic volume); finds that majority of DDoS attacks originate from fewer than 50 hosting companies and regional providers Nokia Deepfield shares strategies for fingerprinting and tracing primary DDoS sources; makes recommendations for addressing DDoS security with networking community Analysis shows more than 100% increase in daily DDoS peak traffic between January 2020 and May 2021 Identifies the threat potential for possible DDoS attacks over 10 Tbps – four to five times the scale of largest attacks reported so far (just above 2 Tbps) – due to rapidly growing number of open and insecure internet services and IoT devices Delivers Nokia Deepfield Defender, specifically designed to safely, securely and efficiently orchestrate DDoS mitigation acr
Ceylon Graphite Announces Licence for Vein Graphite and Graphene Technologies14.6.2021 13:15:00 CEST | Press release
VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Ceylon Graphite Corp. (“Ceylon Graphite”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that it has acquired an exclusive global licence from Cambridge Advanced Materials & Innovation (“CAMI”). The licence pertains to a method of producing high quality few-layer graphene (“FLG”) and derivatives by exfoliation of high grade vein graphite produced by Ceylon Graphite (“The Technology”). This is a low-energy process which results in high-yield, few layer graphene products. This industrial process is already fully designed for large volume production, and is scalable, with modules added as demand increases. Upon completion of the licence agreement, Ceylon Graphite has gained full access to all intellectual property surrounding The Technology and know-how. Use of Ceylon’s high-grade feedstock material- vein graphite - leads to minimal to nil industrial waste during the production of graphene. The combination of uniq
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK14.6.2021 13:00:00 CEST | Press release
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted a Promising Innovative Medicine (PIM) designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease (SCD). Following a review by the MHRA, PIM designations are given to promising treatments that are likely to offer a major advantage for patients and are an early indication that the treatment is a promising candidate for the Early Access to Medicines Scheme (EAMS). For the MHRA to grant a PIM designation, the product must meet each of the following three criteria: The condition should be life-threatening or
Incap Corporation: INCAP CONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED.14.6.2021 10:45:00 CEST | Press release
Incap Corporation 14 June 2021 at 11:45 a.m. (EEST) Stock Exchange Release Insider information INCAPCONTINUES TO RAMP UP ITS FACTORIES IN INDIA, LOCK-DOWN EXTENDED UNTIL 21 JUNE 2021. INCAP’S PREVIOUSLY ANNOUNCED OUTLOOK FOR 2021 REMAINS UNCHANGED. Incap announced on 10 May 2021 that it had temporarily closed down its factories in Tumkur until 24 May 2021. On 24 May 2021, Incap announced that the lock-down had been extended until 7 June 2021 and that it had been granted a permission for partial operation of its factories. Currently, the lock-down in Karnataka has been extended until 21 June 2021. Incap’s factories in India continue to operate according to the government guidelines and Incap is prepared to resume full operations once the restrictions are removed. The closure and the partial operations of the factories in India do not have an impact on the company’s outlook for 2021 published on 21 April 2021. Incap’s previously announced outlook for 2021: Incap estimates that its revenu
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN14.6.2021 10:30:00 CEST | Press release
2022 PAN EUROPEAN LAUNCH OF OKUMA REELS, RODS AND COMBOS BY RAPALA VMC CORPORATION SUPPORTED BY MASSIVE MARKETING CAMPAIGN Rapala VMC Corporation (“Rapala VMC”) announced on January 27, 2021 the acquisition of Okuma European and Russian trademarks and associated intangible assets. Rapala VMC is now pleased to announce that the largescale launch of Okuma reels, rods and combos in Europe and Russia will occur January 1, 2022. Svendsen Sport A/S (“Svendsen“) and Okuma Fishing Tackle Co Ltd (“Okuma”) have recently agreed that Okuma’s long term exclusive distribution agreement with Svendsen covering Denmark, Norway, Sweden, Iceland, UK, Ireland, France, Germany, The Netherlands, Luxembourg, Austria, Belgium, Czech Republic, Hungary, Poland and Russia (“Svendsen Territory”) will terminate effective December 31, 2021 and that Svendsen’s rights to collect pre-orders terminates September 15, 2021. To facilitate a smooth transition, Rapala VMC has agreed to acquire Svendsen’s inventories of Okum
Progress on Brunel share buyback program 202114.6.2021 10:30:00 CEST | Press release
Amsterdam, 14 June 2021 – Brunel International N.V. (Brunel; BRNL), reports the transaction details for the period 7 June 2021 through 11 June 2021 related to its share buyback program announced on 1 June 2021 for an amount up to EUR 1,977,000, and started on 3 June 2021 in order to meet obligations under its performance share plan for senior management (excluding Board of Directors). Detailed information including all individual transactions can be found on https://www.brunelinternational.net/en/share-buyback-program. DateTotal shares repurchasedAverage purchase priceTotal consideration07/06/202111,305€ 11.4980€ 129,984.8908/06/202113,004€ 11.3393€ 147,456.2609/06/202114,164€ 11.2713€ 159,646.6910/06/202113,034€ 11.3668€ 148,154.8711/06/20217,434€ 11.4107€ 84,827.14Total58,941€ 11.3685€ 670,069.85 This press release contains inside information as meant in clause 7 of the Market Abuse Regulation. Attachment Press Release Share Buyback 2021 progress
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme14.6.2021 09:35:04 CEST | Press release
Company Announcement No. 31/2021 Copenhagen, 14 June 2021 Transactions in connection with share buy-back programme On 10 March 2021, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 600 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 28 February 2022. The following transactions have been executed from 7 June to 11 June 2021: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated, last announcement1,241,419154,300,854 7 June 202120,000131.172,623,400 8 June 202120,000130.372,607,494